ATRA Earnings Date: Nov 11, 2026 (Estimated) — Atara Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology
Updated
When is ATRA's next earnings date?
Atara Biotherapeutics, Inc. (ATRA) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 9:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.13 on revenue of $800,000.
How did ATRA do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Atara Biotherapeutics, Inc. posted EPS of -$0.32 versus the -$0.32 estimate, a miss of 28.0%. Revenue was $630,000 against a $550,000 estimate. The stock's 1-day post-earnings move was -7.8%.
How much does ATRA stock move after earnings?
ATRA beat EPS estimates in 3 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 9.3% (up or down) in the day after earnings.
About Atara Biotherapeutics, Inc.
Founded in 2012 and headquartered in South San Francisco, California, Atara Biotherapeutics, Inc. is dedicated to pioneering ready-to-use (off-the-shelf) T-cell immunotherapies. Their primary focus in the United States involves creating treatments for patients battling cancer, autoimmune disorders, and viral infections. A key therapeutic candidate, tabelecleucel, is currently undergoing Phase 3 clinical trials for Epstein-Barr virus (EBV)-driven post-transplant lymphoproliferative disease, as well as various hematologic and solid tumors, such as nasopharyngeal carcinoma. The company is also advancing a robust pipeline of next-generation CAR T immunotherapies designed to combat hematologic malignancies and solid tumors. This includes ATA2271 and ATA3271 targeting mesothelin, alongside ATA2431 and ATA3219 for B-cell malignancies. Furthermore, Atara is developing ATA188 for the treatment of multiple sclerosis and the ATA368 program specifically for cancers associated with human papillomavirus (HPV). To bolster its research and development efforts, Atara Biotherapeutics has established significant collaborations and licensing agreements. These include a licensing partnership with Memorial Sloan Kettering Cancer Center, a license and R&D collaboration with QIMR Berghofer Medical Research Institute, and a strategic alliance with H. Lee Moffitt Cancer Center. Additionally, the company holds a strategic partnership with Bayer AG focused on mesothelin-targeted CAR T-cell therapies for solid tumors.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.32 | -0.32 | -28.00% | $630,000 | ❌ Miss | -7.75% | +4.07% | +1.68% |
| 2026-05-12 | Q1 2026 | 0.32 | -0.29 | -190.62% | $516,000 | ❌ Miss | +6.83% | -4.08% | +6.63% |
| 2026-03-16 | Q4 2025 | -0.07 | -0.25 | -257.14% | $1.6M | ❌ Miss | -10.90% | -17.46% | -10.73% |
| 2025-11-12 | Q3 2025 | -0.73 | -0.32 | +56.16% | $3.5M | ✅ Beat | -0.72% | +7.17% | +41.88% |
| 2025-08-11 | Q2 2025 | -0.32 | 0.19 | +159.38% | $17.6M | ✅ Beat | +11.82% | +11.24% | +14.15% |
| 2025-03-07 | Q4 2024 | -2.48 | -1.19 | +52.02% | $32.8M | ✅ Beat | -10.72% | +5.07% | -16.96% |
| 2024-11-12 | Q3 2024 | -1.93 | -2.93 | -51.81% | $40.2M | ❌ Miss | +22.19% | -5.83% | -6.17% |
| 2024-08-12 | Q2 2024 | -1.56 | -3.10 | -98.72% | $28.6M | ❌ Miss | +3.22% | -7.46% | +6.95% |
Showing last 8 quarters.